UNASSIGNED: 1582 Background: We have shown that extract from @entity1114 , the common white @entity1114 (WBM), contains phytochemicals that suppress aromatase activity, inhibit @entity0 ( @entity0 ) cell proliferation, and decrease mammary @entity5 formation in vivo. We now report a translational clinical trial to determine the optimal dose to induce this effect in @entity1 . METHODS: WBM were freeze-dried and pressed into a tablet containing 500mg of powdered extract, each roughly equivalent to 5g of whole WBM. Postmenopausal @entity1 diagnosed with @entity0 at least 5 years prior, who were at least 3 months off therapy and recurrence-free, were treated with a 12-week course of 5, 8, 10, or 13g of mushroom extract daily. Aromatase inhibition was evaluated with serial serum sex @entity479 hormone and ex vivo plasma aromatase activity (AA) assays. Response was defined as a >= 50% decrease in free @entity53 (FE2). Because immunologic effects have been reported with medicinal mushrooms, cytokines were also measured. RESULTS: WBM extract up to 13g per day was well tolerated, with a median adherence of 95%, 96%, 95%, and 98% on the four escalating doses, respectively (n==6 each). Although no @entity1 met the pre-defined response criterion, FE2 was observed to trend upward over the 12-week treatment course for the 5g and 8g dose groups and remain stable among the 10g and 13g dose groups (p==.05). AA measurements were able to detect a consistent post-prandial peak in activity in the 5g and 8g dose groups (p==.003 and <.001, respectively), which diminished in the 10g group and disappeared in the 13g group. Among @entity1 with detectable baseline cytokine levels, @entity1356 , @entity1199 , and @entity650 decreased on treatment, but there was no clear dose effect. CONCLUSIONS: High doses of WBM extract are well tolerated. An ex vivo assay of aromatase activity developed in our lab is sensitive to short-term changes and demonstrated suppression of post-prandial fluctuations with a 10g or 13g daily dose of WBM extract. These results suggest that anti-aromatase phytochemicals are present in plasma with daily consumption of 100-130g whole WBM, but not at high enough concentrations to significantly reduce @entity172 levels from baseline in 12 weeks.

A dose-finding clinical trial of mushroom powder in postmenopausal @entity0 survivors for secondary XXXX prevention.

@entity1 :: ('9606', 'Species') :: ['women', 'humans', 'patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'BC'] @entity1114 :: ('5341', 'Species') :: ['button mushroom', 'Agaricus bisporus'] @entity1356 :: ('3553', 'Gene') :: ['IL-1b'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity1199 :: ('3558', 'Gene') :: ['IL-2'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
